Molecular mechanism through which Tripterygium hypoglaucum (Lévl.) Hutch alleviates psoriasis

IF 6.9 2区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Biomedicine & Pharmacotherapy Pub Date : 2024-11-06 DOI:10.1016/j.biopha.2024.117647

{"title":"Molecular mechanism through which Tripterygium hypoglaucum (Lévl.) Hutch alleviates psoriasis","authors":"","doi":"10.1016/j.biopha.2024.117647","DOIUrl":null,"url":null,"abstract":"<div><div><em>Tripterygium hypoglaucum</em> (Lévl.) Hutch rhizome (THH) is mainly used in the clinical setting for the treatment of autoimmune diseases such as rheumatoid arthritis. In total, four active compounds were isolated from THH methanol extract （THH-MeOH）and identified. The HPLC results showed that the proportions of the active ingredients in THH-MeOH (i.e., celastrol, triptolide, and 3-<em>O</em>-acetyloleanolic acid) were 0.79 ‰, 0.46 ‰, and 0.76 ‰, respectively. THH-MeOH attenuated the M5-induced hyperproliferation of HaCaT cells, decreased the mRNA expression levels of inflammatory cytokines, and inhibited the phosphorylation of I<em>κ</em>B<em>α</em>, NF-<em>κ</em>B p65, MAPK, and STAT3/JAK2. Furthermore, THH-MeOH significantly reduced PASI scores in mice; reduced the level of Ki67 expression in skin tissues; decreased the expression of inflammatory cytokines in the skin lesions and serum; and ameliorated the IMQ-induced imbalance in the ROR<em>γ</em>t<em>/</em>Foxp3 ratio. The extract can attenuate psoriasis-like lesions by inhibiting cellular hyperproliferation, ameliorating inflammatory reactions, and modulating immune responses. Our work provides a theoretical basis to support the use of THH for treating psoriasis.</div></div>","PeriodicalId":8966,"journal":{"name":"Biomedicine & Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":6.9000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedicine & Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0753332224015336","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Tripterygium hypoglaucum (Lévl.) Hutch rhizome (THH) is mainly used in the clinical setting for the treatment of autoimmune diseases such as rheumatoid arthritis. In total, four active compounds were isolated from THH methanol extract （THH-MeOH）and identified. The HPLC results showed that the proportions of the active ingredients in THH-MeOH (i.e., celastrol, triptolide, and 3-O-acetyloleanolic acid) were 0.79 ‰, 0.46 ‰, and 0.76 ‰, respectively. THH-MeOH attenuated the M5-induced hyperproliferation of HaCaT cells, decreased the mRNA expression levels of inflammatory cytokines, and inhibited the phosphorylation of IκBα, NF-κB p65, MAPK, and STAT3/JAK2. Furthermore, THH-MeOH significantly reduced PASI scores in mice; reduced the level of Ki67 expression in skin tissues; decreased the expression of inflammatory cytokines in the skin lesions and serum; and ameliorated the IMQ-induced imbalance in the RORγt/Foxp3 ratio. The extract can attenuate psoriasis-like lesions by inhibiting cellular hyperproliferation, ameliorating inflammatory reactions, and modulating immune responses. Our work provides a theoretical basis to support the use of THH for treating psoriasis.

查看原文本刊更多论文

Tripterygium hypoglaucum (Lévl.) Hutch 减轻牛皮癣的分子机制。

Tripterygium hypoglaucum (Lévl.) Hutch rhizome（THH）在临床上主要用于治疗类风湿性关节炎等自身免疫性疾病。从THH 甲醇提取物（THH-MeOH）中共分离出四种活性化合物并进行了鉴定。高效液相色谱分析结果表明，THH-MeOH 中的有效成分（即赛拉司特醇、三肽内酯和 3-O-乙酰齐墩果酸）所占比例分别为 0.79 ‰、0.46 ‰ 和 0.76 ‰。THH-MeOH 可减轻 M5 诱导的 HaCaT 细胞过度增殖，降低炎症细胞因子的 mRNA 表达水平，抑制 IκBα、NF-κB p65、MAPK 和 STAT3/JAK2 的磷酸化。此外，THH-MeOH 还能显著降低小鼠的 PASI 评分；降低皮肤组织中 Ki67 的表达水平；降低皮损和血清中炎性细胞因子的表达；改善 IMQ 引起的 RORγt/Foxp3 比率失衡。该提取物可通过抑制细胞过度增殖、改善炎症反应和调节免疫反应来减轻银屑病样皮损。我们的研究为支持使用 THH 治疗银屑病提供了理论依据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomedicine & Pharmacotherapy 医学-药学

CiteScore

11.90

自引率

2.70%

发文量

1621

审稿时长

48 days

期刊介绍： Biomedicine & Pharmacotherapy stands as a multidisciplinary journal, presenting a spectrum of original research reports, reviews, and communications in the realms of clinical and basic medicine, as well as pharmacology. The journal spans various fields, including Cancer, Nutriceutics, Neurodegenerative, Cardiac, and Infectious Diseases.